Literature DB >> 23642736

CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome.

Huijuan Jiang1, Rong Fu, Huaquan Wang, Lijuan Li, Hui Liu, Zonghong Shao.   

Abstract

The increased LSC in MDS has correlation with the progression to AML, which the mechanism of immune evasion is unclear. Our study showed the expression of CD47 on LSC of the patients in high-risk MDS based on IPSS/WPSS score was higher than that of in low-risk MDS and controls. The level of CD47 on erythroblast of MDS patients had a significant positive correlation with their peripheral RBC count. It suggested that the proportion of CD34(+)CD38(-)CD47(+) cells increased in high-risk MDS which might protect LSC from avoiding phagocytosis, and low-expression of CD47 on erythroblast in MDS might be correlated to anemia.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23642736     DOI: 10.1016/j.leukres.2013.04.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

Review 1.  Mutation-Driven Therapy in MDS.

Authors:  David M Swoboda; David A Sallman
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.

Authors:  Sukhbir Kaur; David D Roberts
Journal:  Int J Biochem Cell Biol       Date:  2016-05-06       Impact factor: 5.085

3.  Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

Authors:  Amer M Zeidan; Daniel J DeAngelo; Jeanne Palmer; Christopher S Seet; Martin S Tallman; Xin Wei; Heather Raymon; Priya Sriraman; Stephan Kopytek; Jan Philipp Bewersdorf; Michael R Burgess; Kristen Hege; Wendy Stock
Journal:  Ann Hematol       Date:  2022-01-04       Impact factor: 4.030

4.  CD8+ T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3/Gal-9 pathway.

Authors:  Jinglian Tao; Dong Han; Shan Gao; Wei Zhang; Hong Yu; Pei Liu; Rong Fu; Lijuan Li; Zonghong Shao
Journal:  J Cell Mol Med       Date:  2019-11-22       Impact factor: 5.310

5.  Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.

Authors:  Irène Baccelli; Albrecht Stenzinger; Vanessa Vogel; Berit Maria Pfitzner; Corinna Klein; Markus Wallwiener; Martina Scharpff; Massimo Saini; Tim Holland-Letz; Hans-Peter Sinn; Andreas Schneeweiss; Carsten Denkert; Wilko Weichert; Andreas Trumpp
Journal:  Oncotarget       Date:  2014-09-30

Review 6.  Evidencing the Role of Erythrocytic Apoptosis in Malarial Anemia.

Authors:  Paulo R R Totino; Cláudio T Daniel-Ribeiro; Maria de Fátima Ferreira-da-Cruz
Journal:  Front Cell Infect Microbiol       Date:  2016-12-09       Impact factor: 5.293

7.  Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes.

Authors:  Benjamin N Ostendorf; Eva Flenner; Anne Flörcken; Jörg Westermann
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

Review 8.  Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.

Authors:  Bruno Fattizzo; Juri A Giannotta; Wilma Barcellini
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

Review 9.  Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins.

Authors:  Marcus Bauer; Christoforos Vaxevanis; Nadine Heimer; Haifa Kathrin Al-Ali; Nadja Jaekel; Michael Bachmann; Claudia Wickenhauser; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923

10.  Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes.

Authors:  Dong Han; Jinglian Tao; Rong Fu; Zonghong Shao
Journal:  Innate Immun       Date:  2020-10-13       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.